VALIDation of the IBD-Disk Instrument for Assessing Disability in Inflammatory Bowel Diseases in a French Cohort: The VALIDate Study.


Journal

Journal of Crohn's & colitis
ISSN: 1876-4479
Titre abrégé: J Crohns Colitis
Pays: England
ID NLM: 101318676

Informations de publication

Date de publication:
07 Nov 2020
Historique:
pubmed: 18 5 2020
medline: 7 9 2021
entrez: 18 5 2020
Statut: ppublish

Résumé

Inflammatory bowel diseases [IBD] are disabling disorders. The IBD-Disability Index [IBD-DI] was developed for quantifying disability in IBD patients but is difficult to use. The IBD-Disk is a visual adaptation of the IBD-DI. It has not been validated yet. The main objectives were to validate the IBD-Disk and to assess the clinical factors associated with a change in the score and its variability over time. From May 2018 to July 2019, IBD patients from three university-affiliated hospitals responded twice to both IBD-Disk and IBD-DI at 3-12 month intervals. Validation included concurrent validity, reproducibility, and internal consistency. Mean IBD-Disk scores were compared according to clinical factors. Variability was assessed by comparing scores between baseline and follow-up visits. A total of 447 patients [71% Crohn's disease, 28% ulcerative colitis] were included in the analysis at baseline and 265 at follow-up. There was a good correlation between IBD-Disk and IBD-DI [r = 0.75, p <0.001]. Reproducibility was excellent [intra-class correlation coefficient = 0.90], as well as internal consistency [Cronbach's α = 0.89]. The IBD-Disk was not influenced by IBD type but was associated with female gender and physician global assessment. Extra-intestinal manifestations, history of resection, elevated C-reactive protein and faecal calprotectin also tended to be associated with higher disability. The IBD-Disk score decreased in patients becoming inactive over time. This study validated the IBD-Disk in a large cohort of IBD patients, demonstrating that it is a valid and reliable tool for quantifying disability for both CD and UC.

Sections du résumé

BACKGROUND AND AIMS OBJECTIVE
Inflammatory bowel diseases [IBD] are disabling disorders. The IBD-Disability Index [IBD-DI] was developed for quantifying disability in IBD patients but is difficult to use. The IBD-Disk is a visual adaptation of the IBD-DI. It has not been validated yet. The main objectives were to validate the IBD-Disk and to assess the clinical factors associated with a change in the score and its variability over time.
METHODS METHODS
From May 2018 to July 2019, IBD patients from three university-affiliated hospitals responded twice to both IBD-Disk and IBD-DI at 3-12 month intervals. Validation included concurrent validity, reproducibility, and internal consistency. Mean IBD-Disk scores were compared according to clinical factors. Variability was assessed by comparing scores between baseline and follow-up visits.
RESULTS RESULTS
A total of 447 patients [71% Crohn's disease, 28% ulcerative colitis] were included in the analysis at baseline and 265 at follow-up. There was a good correlation between IBD-Disk and IBD-DI [r = 0.75, p <0.001]. Reproducibility was excellent [intra-class correlation coefficient = 0.90], as well as internal consistency [Cronbach's α = 0.89]. The IBD-Disk was not influenced by IBD type but was associated with female gender and physician global assessment. Extra-intestinal manifestations, history of resection, elevated C-reactive protein and faecal calprotectin also tended to be associated with higher disability. The IBD-Disk score decreased in patients becoming inactive over time.
CONCLUSIONS CONCLUSIONS
This study validated the IBD-Disk in a large cohort of IBD patients, demonstrating that it is a valid and reliable tool for quantifying disability for both CD and UC.

Identifiants

pubmed: 32417910
pii: 5838423
doi: 10.1093/ecco-jcc/jjaa100
doi:

Types de publication

Clinical Trial Journal Article Multicenter Study Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1512-1523

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Catherine Le Berre (C)

Institut des Maladies de l'Appareil Digestif, Nantes University Hospital, Nantes, France.

Mathurin Flamant (M)

Institut des Maladies de l'Appareil Digestif, Nantes University Hospital, Nantes, France.
Centre d'Investigation Clinique, Nantes University Hospital, Nantes, France.

Guillaume Bouguen (G)

Service des Maladies de l'Appareil Digestif, Rennes University Hospital, Rennes, France.

Laurent Siproudhis (L)

Service des Maladies de l'Appareil Digestif, Rennes University Hospital, Rennes, France.

Marie Dewitte (M)

Service des Maladies de l'Appareil Digestif, Rennes University Hospital, Rennes, France.

Nina Dib (N)

Service de Gastroentérologie, Angers University Hospital, Angers, France.

Elodie Cesbron-Metivier (E)

Service de Gastroentérologie, Angers University Hospital, Angers, France.

Thomas Goronflot (T)

Clinique des Données, Nantes University Hospital, Nantes, France.

Matthieu Hanf (M)

Clinique des Données, Nantes University Hospital, Nantes, France.

Pierre-Antoine Gourraud (PA)

Clinique des Données, Nantes University Hospital, Nantes, France.

Elise Kerdreux (E)

Centre d'Investigation Clinique, Nantes University Hospital, Nantes, France.

Alexandra Poinas (A)

Direction de la Recherche Clinique, Nantes University Hospital, Nantes, France.

Arnaud Bourreille (A)

Institut des Maladies de l'Appareil Digestif, Nantes University Hospital, Nantes, France.
Centre d'Investigation Clinique, Nantes University Hospital, Nantes, France.

Caroline Trang-Poisson (C)

Institut des Maladies de l'Appareil Digestif, Nantes University Hospital, Nantes, France.
Centre d'Investigation Clinique, Nantes University Hospital, Nantes, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH